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Background: Orphan drug development faces numerous challenges, including low disease prevalence, patient
population heterogeneity, and strong presence of paediatric patient populations. Consequently, clinical trials for
orphan drugs are often smaller than those of non-orphan drugs, and they require the development of efficient trial
designs relevant to small populations to gain the most information from the available data. The International Rare
Diseases Research Consortium (IRDiRC) is aimed at promoting international collaboration and advance rare diseases
research worldwide, and has as one of its goals to contribute to 1000 new therapies for rare diseases. IRDiRC set up
a Small Population Clinical Trials (SPCT) Task Force in order to address the shortcomings of our understanding in
carrying out clinical trials in rare diseases.
Results: The IRDiRC SPCT Task Force met in March 2016 to discuss challenges faced in the design of small studies
for rare diseases and present their recommendations, structured around six topics: different study methods/designs
and their relation to different characteristics of medical conditions, adequate safety data, multi-arm trial designs,
decision analytic approaches and rational approaches to adjusting levels of evidence, extrapolation, and patients’
engagement in study design.
Conclusions: Recommendations have been issued based on discussions of the Small Population Clinical Trials Task
Force that aim to contribute towards successful therapy development and clinical use. While randomised clinical
trials are still considered the gold standard, it is recommended to systematically take into consideration alternative
trial design options when studying treatments for a rare disease. Combining different sources of safety data is
important to give a fuller picture of a therapy’s safety profile. Multi-arm trials should be considered an opportunity
for rare diseases therapy development, and funders are encouraged to support such trial design via international
networks. Patient engagement is critical in trial design and therapy development, a process which sponsors are
encouraged to incorporate when conducting trials and clinical studies. Input from multiple regulatory agencies is
recommended early and throughout clinical development. Regulators are often supportive of new clinical trial
designs, provided they are well thought through and justified, and they also welcome discussions and questions on
this topic. Parallel advice for multiregional development programs should also be considered.
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The development and evaluation of drugs, biologics and
devices, intended for the treatment of rare diseases, is
often accomplished in small clinical trials. Rare diseases
are characterized by a low prevalence. Different jurisdic-
tions use different criteria for designating “rare” (or “or-
phan”): for example, fewer than 200,000 people affected
by the condition in the US, fewer than 1 in 2000 people
in the European Union, and fewer than 50,000 people in
Japan [1–3]. However, many rare diseases may only
affect a few hundred or a few thousand patients world-
wide. Consequently, trials set up in these low prevalence
conditions face many challenges, including heterogeneity
in the patient population, difficulty in clinical trial re-
cruitment, poorly understood natural history of the dis-
ease and often presentation in children, which brings
additional challenges in clinical trials and trial design.
To enhance the development of drugs for rare diseases,
incentives have been implemented in the United States,
the European Union and Japan, most notably through the
US Orphan Drug Act of 1983 [1], the EU Regulation on
orphan medicinal products (Regulation EC No 141/2000)
[2], and in Japan Article 77–2 of the Pharmaceutical Af-
fairs Law for orphan drugs [3] respectively. These incen-
tives and others have shown moderate success [4–6] but
the needs of patients with rare diseases are still insuffi-
ciently met at present [7]. This confirms the continuing
need for efficient trial designs relevant to small popula-
tions to assure continued development of new treatments
for rare diseases, especially when traditional randomised
control trial designs are not possible due to limited num-
ber of available patients.
Further progress is needed in trial design aiming to as-
sess medicines in a cost-effective, rigorously controlled
manner, and in parallel with relevant analysis methods
to assess treatment effects in small heterogeneous popu-
lations. These design options must also respect the need
for reliable evidence prior to offering treatments to pa-
tients in need [8]. Therefore, developing design and ana-
lysis methodologies of clinical trials in small population
settings requires a rigorous approach from all stake-
holders, including regulators and patients. Several inter-
national initiatives and international actors are currently
working to contribute to innovative solutions for small
population studies [9–13].
The IRDiRC Small Population Clinical Trials Task Force
The International Rare Diseases Research Consortium
(IRDiRC) was set up in 2011 to coordinate and accelerate
research, and to maximise scarce resources in the field of
rare diseases [14]. It unites governmental and non-profit
funding bodies, companies, umbrella patient advocacy
organizations, and scientific researchers to promote inter-
national collaboration and advance rare diseases researchworldwide. The Consortium is aimed at promoting inter-
national collaboration in rare diseases research and de-
velopment worldwide, and has as one of its goals to
contribute to the development 1000 new therapies for rare
diseases. Its vision is to: Enable all people living with a rare
disease to receive an accurate diagnosis, care, and available
therapy within 1 year of coming to medical attention [15].
Three Scientific Committees (Diagnostics, Interdisciplin-
ary, Therapies) advise the IRDiRC Consortium Assembly
on research priorities and scientific progress. The Therap-
ies Scientific Committee has issued recommendations [16]
to address bottlenecks associated to health research in low
prevalence but high need conditions, which are expected
to foster the development of rare disease therapies on a
global scale. Following issuance of these recommendations,
IRDiRC launched several Task Forces to address specific is-
sues. One of these is the Task Force on Small Population
Clinical Trials (SPCT), set up to address the shortcomings
of our understanding in small population clinical trials for
rare diseases and to issue recommendations to ensure that
methods used for such trials are conducive to ultim-
ately making effective therapies available for patients
[17]. Task Force members include researchers, industry
representatives, regulatory agency representatives, and
patient advocacy representatives. The Task Force held a
workshop in March 2016 and this paper is based on the
workshop outcome of this Task Force.
Regulatory agency guidelines
Drugs for the treatment of rare diseases must demon-
strate substantial evidence of clinical benefit in adequate,
well-controlled studies. Different incentives exist for prod-
ucts that are granted orphan drug designation; however, no
markedly different assessment standards are routinely used
for orphan drugs in comparison to non-orphan drugs. The
US Food and Drug Administration (FDA) and European
Medicines Agency (EMA) have developed guidelines to
support the design of clinical trials for small populations.
The EMA’s Committee for Medicinal Products for
Human Use (CHMP) guideline states that “no methods
exist that are relevant to small studies that are not also
applicable to large studies” [18]. Nonetheless, the guide-
line also states that less commonly seen methodological
designs may be acceptable in small population condi-
tions if they might help improve the interpretability of
the results of the study. The EMA highlights that the
trade-off between small quantities of high quality evi-
dence (from small randomised trials) and large quantities
of lower quality evidence (from larger uncontrolled case
series) must be considered and judged on a case-by-case
basis. Marketing authorisation applications for orphan
products tested in small populations are assessed accord-
ing to the same standards as those for other products but
consider limitations due to low patient recruitment. If
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are open to discuss the adoption of alternative meth-
odologies and evidence sources to enhance the overall
evidence base.
The FDA acknowledges the challenges of small popu-
lation clinical trial development for rare diseases and has
provided draft guidance to assist sponsors of drugs and
biological products intended to treat or prevent rare dis-
eases [19] wherein strategies were proposed for use in
randomised control trial settings to support safety and
efficacy claims in different drug development phases. In
2010, a draft “Guidance for Industry – Adaptive Design
Clinical Trials or Drugs and Biologics” was published to
provide guidance to sponsors for the development of
adaptive clinical trials [20]. While being cautious to the
risks associated with adaptive clinical trials, the docu-
ment does provide guidance on modifications that can
be planned in a prospectively written protocol, including
eligibility criteria, randomisation procedure, total sample
size, and endpoints. Caution should however be taken
concerning the generalisability and applicability of adap-
tive clinical trial results. Various strategies may aim to
decrease heterogeneity, improve disease characterization
and predicted clinical course, which could thereby shape
patient selection prior to randomisation but do not
generally reduce statistical validity regarding the study
population. The FDA furthermore encourages early
communication to assist in drug evaluation, scientific,
and medical questions that may arise throughout the
clinical investigation. Better communication at clinical
stages and around Special Protocol Assessments with
the review divisions increases the chance of successful
clinical outcomes.
The Pharmaceuticals and Medical Devices Agency
(PMDA) in Japan has a guidance document for staff
involved in new drug evaluations, entitled “Points to
be considered by the review staff in the evaluation
process of new drug” [21]. It is stated that - in par-
ticular for orphan drugs - final decisions should not
be exclusively based on points covered in the docu-
ment, but that points such as the clinical relevance
should also be taken into account. Also, scientific
evaluation should be based on the entirety of the
document. No specific guidance document on small
population studies is currently available but a guid-
ance document on methodological issues related to
these studies is expected to be developed. Neverthe-
less, PMDA offers consultation to give guidance and
advice on clinical trials and on data for regulatory
submissions. Specifically, for the development of or-
phan drugs with small population clinical trials,
PMDA offers advice on alternatives to traditional
methodologies at face-to-face meetings during early
development stages.Paper outline
This paper outlines the recommendations of the IRDiRC
SPCT Task Force that are structured around seven topics:
“General recommendations”, “Different study methods/
designs related to characteristics of medical conditions”,
“Adequate safety data”, “Multi-arm designs”, “Decision
analytic approaches and rational approaches to adjusting
levels of evidence”, “Extrapolation”, and “Patients’ engage-
ment in study design.” Each topic briefly explores the
different recommendations set out by the Task Force to
encourage, support and develop small population studies.
The paper includes the results of the discussion concern-
ing recent options and points to consider when designing
small population clinical trials with special focus on rare
diseases. The paper is not intended to give detailed expla-
nations of methodological approaches – instead the reader
should refer to common statistical texts or, in many cases,
current research literature. A number of points for further
discussion are also suggested, which future IRDiRC Task
Forces (or other initiatives or regulatory agencies) might
contribute to.
Recommendations by the IRDiRC Small Population Clinical
Trials Task Force
General recommendations
 When feasible, make full use of longitudinal data:
Analysis methods for repeated measurements lead
to a potential reduction of sample size by 30%
versus change score analysis [22]. Such designs allow
for the modelling of the development of the
treatment effect, not just its existence (or otherwise)
at a specified follow-up point. The question an-
swered by such an analysis (or the “estimand”) is
different to a simple analysis at a fixed time point, so
the relevance of the question of “how the treatment
effect develops” rather than “what is the effect at a
given time” needs to be considered.
 Do not dichotomise continuous endpoints in the
primary analysis (although possibly do so for
sensitivity analyses and assessment of clinical
relevance). Many measurements in medicine are
inherently continuous measurements (for example,
blood pressure) but there is often a wish to
dichotomise patients as “responders” or “non-
responders”. It is argued that differences in
responder rates may have more clinical relevance
than differences of means. Whether that is true or
not may be case-dependent, but dichotomising will
nearly always be an inefficient use of data, requiring
more patients to demonstrate the existence of
treatment effects.
 Trials should be long enough for complete follow up
and patients should stay in trials for as long as
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outcomes: in survival trials this can substantially
reduce censoring, and in longitudinal data studies it
increases the amount of information available.
Unfortunately, additional costs can be connected to
longer clinical trials but those costs should be
balanced against the greater information gained from
longer follow up.
 Use analysis of covariance (ANCOVA) instead of
simple “change from baseline” analyses for
reduction of bias and gains in efficiency [23].
ANCOVA is always more efficient than the similar
“change from baseline” analysis. It accounts for
imbalances at baseline more properly than “change
from baseline” analyses, and it accounts for the
correlation between baseline and endpoint
measurements more properly than does a “change
from baseline” analysis. ANCOVA need not be
restricted to situations where the same variable is
measured at baseline as at the trial endpoint.
 Use multiple endpoints, aimed at multiple study
objectives, but with careful consideration of
multiplicity problems [24]. Multiplicity problems are
just as applicable in studies of rare diseases but the
need to gain as much information from a limited
patient population (in a rare disease) may be greater
than that need in a more common condition.
 Use composites endpoints, by combining several
outcomes into a single outcome measure, thereby
increasing the number of events and hence the
statistical power if treatment is likely to impact all
single outcomes of the composite in the same
direction. Composite endpoints are not without
limitations and it is important to ensure all
individual components of the composite are of
similar clinical importance.
 Use different formulations, doses and endpoints if
appropriate in different subpopulations and consider
the possibility to combined analyses of these
different groups. Examples of this may be when
treating a wide age range when a treatment may
have a similar effect in each age group, but the
scales to measure the endpoint may need to be
different. Methods to combine significance levels are
well established [25], although less so for estimating
the size of treatment effects.
 There is an ongoing need for rigorously collected
natural history and patient registry data for rare
diseases for the design of clinical trials. Natural
history and patient registry data will both add to our
understanding of how diseases progress and develop
over time, but also assist in the determination of the
endpoints where a clinically meaningful difference
can be determined [26]. The FDA has recentlyawarded six research grants in this area, specifically
to “inform medical product development by better
understanding how specific rare diseases progress
over time [27].” Given such understanding, it may
become more viable to use natural history or patient
registry data as an external control arm in clinical
trials, rather than always relying on randomised
controls.
Different study methodologies related to characteristics
of medical conditions
The gold standard for clinical trials is well known: rando-
mised clinical trials with endpoints that are clear and
meaningful to patients [28]. Nevertheless, adequately pow-
ered studies in rare diseases are not always a possibility.
Trial designers should consider different design options
and discuss their applicability with respect to efficiency
and risk of bias. The applicability of each will depend,
amongst other things, on the type of condition being
studied – e.g. stable or highly variable, short or long-term
endpoints, life limiting or symptom control, etc. Further-
more, risks of and opportunities for alternative trial designs
should be discussed. Within the orphan drug development
context, particularly in small trials, a discussion of appro-
priateness of the randomisation procedure as a design
option is important. To assist choosing a suitable trial
design, the following points should be considered:
 Whenever feasible, the gold standard - randomised
clinical trial, with a clinically-relevant endpoint and
long follow-up - should be used.
 For stable diseases with relatively short treatment
duration, and where there are sufficient data to
determine an appropriate washout period, cross-
over designs [29] should be considered since these
may allow potential large reductions in sample size.
Such designs allow each subject to receive both (or
perhaps more than two) interventions but will not
be applicable in, for example, highly variable
conditions or those where very long follow-up is
needed. They are more applicable to relatively
short term endpoints for stable diseases.
 Group-sequential designs [30]: The possibility of
early stopping provides a potential reduction of
sample size but they may also increase study size in
some circumstances. Such designs incorporate
interim analyses (which will usually necessitate use
of a Data Monitoring Committee [31, 32]) and
whilst they have advantages of potentially identifying
early efficacy signals, they also may have the
disadvantage of limited efficacy data in important
subgroups and reduced the extent of safety data.
 Inferentially seamless adaptive designs [33, 34]:
These designs can combine data from an
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selecting appropriate doses) with data from the
confirmatory “phase 3 part” of the same trial. There
are many challenges with such designs, both in the
time needed to design them and appropriate
analyses to adjust for possible bias in estimates of
treatment effect and proper control of type I error.
 If historical data are available, e.g. from registries or
other control events, this may be helpful, but need to
be properly weighted so that they do not overly
influence a final trial conclusion more than the data
from the trial [35, 36]. The relevance of historical data
(considering changing diagnostic ability and changing
standards of care) need to be carefully considered.
 Explore the options for trial designs that allow
subjects to be used more than once (for example
multiple n-of-1 trials, crossover trial designs or
randomised withdrawal designs [37]). In particular,
n-of-1 trials are an ideal tool for comparing the
effects of multiple treatments in individual
patients, but may be less suited to establishing
treatment policies. They have many similarities
with patient-preference designs [38].
It is recommended that trialists should always consider
different design options, quantify what could be gained
from each trial design, and carry out a comprehensive
risk assessment before choosing a particular trial design.
Many designs will often be possible, but the risks and
benefits of each should be carefully evaluated to arrive at
an evidence-driven choice of design. However, as well as
creativity in trial design, it should be kept in mind that
simplicity is often a virtue and unnecessary complexity
of trial designs is to be discouraged.
Adequate safety data
Safety is an essential component of the benefit-risk profile
in the design of small population clinical trials. It is, how-
ever, never possible to state a definition of what consti-
tutes adequate safety data as this depends on the nature of
the disease and the product under investigation. In
addition to the limited size of the intended population, the
adequacy of the safety database depends on multiple fac-
tors, including the nature and severity of adverse events
associated with the product during clinical development,
the magnitude of benefit associated with the product in
the studies that provides the primary evidence of effective-
ness, and the patients’ tolerance for risk.
In small studies, clinical trial data alone typically do
not give sufficient safety data. Therefore, it is important
that several data sources are combined to give a fuller
picture of the safety profile. Sources of data - not only
restricted to clinical trial data - with a safety element in
them include: Registry data
 Electronic health records (especially for drugs that
are already in use, and that are considered as
repurposing candidates)
 Non-clinical data (e.g. animal models). Such data
almost always contribute to, for example,
reproductive toxicity assessments but equivalent-dose
(animal species-to-human) should also be considered
when trying to predict on- and off-target toxicities.
 Post-marketing/ post-approval safety data (encourage
health-care professionals to report adverse events)
 Extrapolation of data with similar compounds
(questions should be considered about what would
be the regulatory acceptability of these data; may be
of interest for drug repurposing in specific
populations)
 Data arising from comprehensive Risk Management
Plans [39] agreed during, and initiated after
licensing. Risk Management Plans are even more
important in the setting of drug approvals being
based on limited data since there are inevitably more
“unknowns” than for a new product entering the
marketplace based on fuller pre-approval data. Such
a plan to continue to monitor a new medicine, and
collect further data, should monitor aspects such as
a medicine’s safety profile, how its risks will be
prevented or minimised in patients, plans for studies
and other activities to gain more knowledge about the
safety and efficacy of the medicine, and measuring the
effectiveness of risk-minimisation measures.
 Social media data (although ownership issues need
to be addressed prior to usage)
 Use of product outside the clinical trial, e.g. in
compassionate use setting that is “off label” but still
covered by appropriate regulatory oversight [40].
Some of the above-mentioned sources are currently un-
derused. It is recommended that researchers be better in-
formed about the value of these data and how they might
be used which, in return, will also improve contributions
towards these different data sources. Additionally, to make
better use of these sources, it is recommended that a pro-
spective quality control system be put in place.
Regulatory approval should not put an end to collection
of safety data; certainty and confidence will increase as
post-marketing data are collected and analysed. There is,
however, a balance needed between more data, potentially
of lesser quality, and better controlled data. Improving the
quality of the post-approval data should be given more
attention and prioritised.
Multi-arm designs
Multi-arm trials, platform trials, basket trials, etc. [41]
are trials that incorporate several treatments in several
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necessarily identical) indications, possibly sharing a com-
mon control. The different treatments and trial arms might
or might not start at the same time, and treatment arms
might be added or dropped as the trial progresses. This
trial design may be used in a proof-of-concept Phase II or,
possibly, in a definitive Phase III trial. An example of
multi-arm trial is the Phase II series of I-SPY trials [42, 43].
This topic was discussed separately from the general
one of different study methodologies related to charac-
teristics of medical conditions because many of those
considerations can apply within a multi-arm design so
that both sections need to be considered in parallel.
Ideas and approaches within “platform trials” are more
specific than, for example, a 3-arm trial of a new active vs.
existing active vs. placebo.
Potential advantages of these types of trial designs are:
 Efficiency of potentially sharing the same control
group
 Diminished chance for patients to receive a placebo,
thereby encouraging participation
 Comparison of active substances
 Pooling data from active treatments, when feasible
 Sharing of resources, thus diminished trial costs,
therefore contributing to efficient use of trial logistics.
Challenges of these trial designs are:
 In case trial treatments are from different sponsors,
there is the need for sponsors to cooperate and
agree to a common protocol
 Need for additional time to design such a complex
study
 Challenges of operating the clinical trial
 Challenges of trial leadership
 Differences of interest between competitive
companies, charities, investigators
 Potential heterogeneity and thus loss in efficiency
due to heterogeneous settings.
Multi-arm trials should be considered as an opportunity
by trial funders, patient organisations and other stake-
holders for studies in rare diseases. Expertise centres, such
as the European Reference Network for rare diseases,
should try to channel patient flow towards this trial design
if possible [44, 45]. Funders should be encouraged to fund
multi-arm trials via international networks to test and
compare multiple treatments more efficiently.
Decision analytic and rational approaches to adjusting
levels of evidence
If knowledge is available about a treatment, how do trial-
ists make the best decisions, and which standards ofevidence are required for decision making? In the topic of
decision analytic and rational approaches to adjusting the
level of evidence, three main questions were discussed.
The first, in addressing decision making when sufficient
information is available for a treatment, several aspects
should be considered, such as:
 Benefit-risk assessment – whilst some evidence for
efficacy may exist, and concern about harms
(adverse reactions to new medicines) will always
exist, still the balance of benefits and risks may be
acceptable. And the perspective of “acceptable” may
differ for different stakeholders (see below).
 The patient horizon – i.e. in an (ultra) rare
condition, the number of patients in the trial may be
relatively “large” compared to the number who may
potentially benefit (within a reasonable time frame)
after the treatment becomes available. This may
influence the decision concerning when there is
enough evidence to start treating all eligible patients.
Ethical judgment and the balance of benefits of
faster access for patients to medicines compared
with the benefits of attaining stronger evidence.
 The different stakeholder perspectives – however
compassionate clinical trialists may be, the
perspective of the patients will often be different to
that of the researcher, the regulator, the prescriber,
the purchaser, etc. In some cases, it may be just as
appropriate to consider the public health impact of
not giving treatment, as well as the more commonly
considered risk (in terms of benefits vs. risks) of
giving a treatment.
 The rate of innovation and how soon further
(possibly better) alternative treatments may be
expected to come to the marketplace.
The second question relates to the standards of evidence
required in decision making. It is important to realise that
the same standard of evidence may not be appropriate in
every disease, especially when the number of patients who
may benefit from the treatment is small. From a statistical
perspective, some think significance levels less stringent
than 5% (e.g. considering a p-value of 10% or 15% as indi-
cative of a significant effect) should be accepted, while
others believe that more stringent levels (e.g. p-values of
1%, or less) should be used. This indicates the potential to
make decisions based on weaker levels of evidence com-
pared to those of more common diseases. Additionally,
although not relevant to regulatory approval, standards of
evidence required by reimbursement bodies should also
be taken into account.
The final question concerns technical issues regarding
decision analytic approaches. These approaches extend
beyond the relatively simply issue of analysing data and
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harms, to the far more difficult problem of deciding what
action to take (e.g. license a drug, or not; prescribe it, or
not; pay for it, or not; take the medicine, or not, etc.). Such
decisions inevitability rely partly on prior beliefs about the
effects of a new therapy: one that is “very likely” to work
may need less compelling data (from a trial) to convince
someone to take it. In contrast, a new therapy that, for
whatever reasons, seems “very unlikely” to be safe and
effective will need more evidence to persuade someone to
take it. Here, the term “prior information” comes into play
and one issue often discussed is that of difficulties and
methods for elicitation of informative Bayesian prior
distributions [46].
No solid conclusions or recommendations were reached
on this topic at the time the workshop was held, although
it may be that such thinking in the context of rare diseases
might trigger a fundamental re-think of the levels of evi-
dence we typically require in many settings. In addition,
the consortia of scientists formed by IDeAl [47], ASTERIX
[48] and InSPiRe [49] have worked on these problems [10]
(as well as many others).
Extrapolation
Extrapolation is defined, according to the EMA, as “ex-
tending information and conclusions available from stud-
ies in one or more subgroups of the patient population
(source population), or in related conditions or with related
medicinal products, to make inferences for another sub-
group of the population (target population), or condition or
product, thus reducing the need to generate additional in-
formation (types of studies, design modifications, number
of patients required) to reach conclusions for the target
population, or condition or medicinal product” [50].
Extrapolation has been mostly discussed as a strategy
to use for paediatric patient populations to address the
practical and ethical difficulties they present when con-
sidering conducting clinical trials [51]. Extrapolation has
been used to maximise the use of available data and to
minimise the exposure of children to unnecessary clin-
ical trials. On 1 April 2016, the EMA released a reflec-
tion paper on extrapolation [52]. Accordingly, data to
support extrapolation of efficacy can come from many
sources, not only pharmacokinetic/ pharmacodynamic
models but also registries, off-label data, and electronic
health records. The quantity and quality of data to be
used for extrapolation, as well as the time for extrapola-
tion (early phase trials, late phase trials), still need to be
considered on a case-by-case basis. In the guidance
paper from the FDA, it is described that if data already
exist that are relevant to another (paediatric) indication
and the evidence is of a scientifically rigorous nature, it
may be possible to extrapolate the data in support of
demonstrating a reasonable assurance of effectiveness,probable benefit and/or safety, but this approach should
be used with care [53]. For sponsors that consider the
use of extrapolation, it is recommended that they engage
with regulators early in development planning.
There is currently limited experience in extrapolating
from one rare disease study to another, or from one popu-
lation to another, e.g. how to extrapolate data in the con-
text of paediatric investigation plans. It is recommended
that examples, preferably with clear illustration of their
advantages, pitfalls and proper use be outlined and/or
developed, including their methods of validation. There is
also a gap in education which should be addressed; a com-
mon language between clinicians, biostatisticians, and
modelling and simulation experts is needed.
Patients’ engagement in study design
Patients’ voices and patient centeredness are essential in
the set-up of clinical trials [35] but at present, there is
no clear process describing how best to incorporate pa-
tients’ contributions in design and interpretation of tri-
als. Patient involvement concerns many aspects of trial
design including safety, benefit-risk assessment and end-
points. Consultation with patients experienced in clinical
trials is advised, and the earliest consultation is pre-
ferred. When patient preference is important in regula-
tory decision-making, carefully designed patient
preference studies should be considered as part of the
clinical development process.
The process of incorporating patients’ feedback into
the trial process is still relatively new to the pharmaceut-
ical industry, therefore guidance - on the topics of when
patient engagement is essential, how and when patient
engagement should be sought, and from which particu-
lar group of patients - from regulators as well as patient
organisations is highly valuable and should be provided.
The drafting of a best practice guidance document for
the interactions between stakeholders of a clinical trial
(sponsors, regulators, patients and patient advocates) is
recommended. This best practice document should pro-
vide information about patient representation in trial
design, focus on the potential benefit of consultation of
patients and/or patient representatives, and how to man-
age potential conflicts of interest.
Conclusions
This article described a summary of the expert discus-
sions on methods for small population clinical trials that
resulted from the IRDiRC SPCT Task Force workshop
for rare diseases. These recommendations aim to con-
tribute towards successful therapy development which
ultimately leads to effective therapies becoming available
to patients, and raise awareness of many possibilities for
studies in rare diseases that all stakeholders should be
aware of. While the randomised clinical trial is still
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trialists look systematically at alternative design options
when setting up a clinical trial for a rare disease. Not
every rare disease trial is as challenging as others, but if
a randomised control design is not feasible, other trial
options should be considered.
Combining all possible sources of safety data, i.e. lon-
gitudinal data, multiple endpoints, adjusting for baseline
in the best possible way, is important to give a fuller pic-
ture of a therapy’s safety profile. Multi-arm trials should
be considered an opportunity for rare diseases therapy
development, and funders are encouraged to support
such trial designs via international networks. Patient en-
gagement is critical in trial design and therapy develop-
ment, a process which sponsors are encouraged to
incorporate when designing and conducting trials and
clinical studies.
Better use of scientific advice from regulators regarding
small population clinical trials should be promoted. Regu-
lators are often supportive of new clinical trial designs,
provided they are well thought through and justified, and
they also welcome discussions and questions on this topic.
Parallel advice for multiregional development programs
should also be considered.
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